Biolinq, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, today announced a $100 million Series C financing led by Alpha Wave Ventures, with participation from existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital.

Biolinq is a healthcare technology company pioneering precision multi-analyte wearable sensors to improve metabolic health. The company's biosensor platform is designed to inform and inspire with unparalleled simplicity to support healthier living. With microsensors that reside just below the skin's surface, Biolinq is redefining the future of continuous biosensing.